Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging

Next Previous
Trial Profile

Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Kaposi's sarcoma
  • Focus Diagnostic use
  • Sponsors Navidea Biopharmaceuticals

Most Recent Events

  • 04 Jun 2015 According to Navidea Biopharmaceuticals media release, the data from this trial will be presented at 18th international workshop on Kaposis Sarcoma HerpesVirus (KSHV) and Related Agents in Hollywood, Florida.
  • 03 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 22 Apr 2015 Complete results will be presented in the coming months, as per Navidea Biopharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top